Gensight Biologics Sa Stock Current Valuation
| SIGHT Stock | EUR 0.24 0.02 7.69% |
Valuation analysis of Gensight Biologics helps investors to measure Gensight Biologics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Gensight Biologics' price fluctuation is out of control at this time. Calculation of the real value of Gensight Biologics is based on 3 months time horizon. Increasing Gensight Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Gensight Biologics' intrinsic value may or may not be the same as its current market price of 0.24, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.24 | Real 0.21 | Hype 0.24 | Naive 0.26 |
The intrinsic value of Gensight Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gensight Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gensight Biologics SA helps investors to forecast how Gensight stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gensight Biologics more accurately as focusing exclusively on Gensight Biologics' fundamentals will not take into account other important factors: Gensight Biologics SA Company Current Valuation Analysis
Gensight Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gensight Biologics Current Valuation | 150.19 M |
Most of Gensight Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gensight Biologics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Gensight Biologics SA has a Current Valuation of 150.19 M. This is 98.95% lower than that of the Biotechnology sector and 96.77% lower than that of the Health Care industry. The current valuation for all France stocks is 99.1% higher than that of the company.
Gensight Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gensight Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gensight Biologics could also be used in its relative valuation, which is a method of valuing Gensight Biologics by comparing valuation metrics of similar companies.Gensight Biologics is currently under evaluation in current valuation category among its peers.
Gensight Fundamentals
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (6.59) % | |||
| Current Valuation | 150.19 M | |||
| Shares Outstanding | 46.16 M | |||
| Shares Owned By Insiders | 12.75 % | |||
| Shares Owned By Institutions | 35.65 % | |||
| Price To Book | 50.99 X | |||
| Price To Sales | 33.81 X | |||
| Revenue | 5.28 M | |||
| Gross Profit | 7.71 M | |||
| EBITDA | (25.52 M) | |||
| Net Income | (28.62 M) | |||
| Cash And Equivalents | 44.29 M | |||
| Cash Per Share | 1.06 X | |||
| Total Debt | 12.1 M | |||
| Debt To Equity | 14.40 % | |||
| Current Ratio | 3.65 X | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (17.14 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 9.8 | |||
| Number Of Employees | 44 | |||
| Beta | 2.16 | |||
| Market Capitalization | 144.58 M | |||
| Total Asset | 56.65 M | |||
| Z Score | 6.6 | |||
| Net Asset | 56.65 M |
About Gensight Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gensight Biologics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gensight Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gensight Biologics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.